目的 探討復(fù)方木尼孜其顆粒聯(lián)合依美斯汀治療慢性蕁麻疹的臨床療效。方法 選取2021年6月—2023年9月開(kāi)灤總醫(yī)院林西醫(yī)院收治的慢性蕁麻疹患者148例，依據(jù)用藥情況將患者分為對(duì)照組（74例）和治療組（74例）。對(duì)照組患者口服富馬酸依美斯汀緩釋膠囊，1粒/次，2次/d。在對(duì)照組的基礎(chǔ)上，治療組口服復(fù)方木尼孜其顆粒，6 g/次，3次/d。兩組用藥15 d。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀緩解時(shí)間，蕁麻疹活動(dòng)度評(píng)分（UAS）和慢性蕁麻疹生活質(zhì)量問(wèn)卷評(píng)分量表（GU-Q2oL）評(píng)分，血清白細(xì)胞介素-33（IL-33）、血清淀粉樣蛋白（SAA）、D-二聚體（D-D）和干擾素-γ（IFN-γ）水平。結(jié)果 治療后，治療組臨床總有效率為95.94%，明顯高于對(duì)照組總有效率（86.49%，P＜0.05）。治療后，治療組患者癥狀緩解時(shí)間均明顯早于對(duì)照組（P＜0.05）。治療后，兩組患者UAS評(píng)分和GU-Q2oL評(píng)分明顯低于治療前（P＜0.05），且治療組評(píng)分均低于對(duì)照組（P＜0.05）。治療后，兩組患者血清IL-33、SAA和D-D水平明顯降低，而INF-γ水平則明顯升高（P＜0.05），且治療組明顯好于對(duì)照組（P＜0.05）。結(jié)論 復(fù)方木尼孜其顆粒聯(lián)合依美斯汀治療慢性蕁麻疹能有效改善臨床癥狀，顯著提升蕁疫能力及生活質(zhì)量，減弱機(jī)體內(nèi)炎性反應(yīng)。

Objective To explore the clinical effect of Compound Muni Ziqi Granules combined with emedastine in treatment of chronic urticaria. Methods Patients (148 cases) with chronic urticaria in Linxi Hospital of Kailuan General Hospital from June 2021 to September 2023 were divided into control (74 cases) and treatment (74 cases) group based on different treatments. Patients in the control group were po administered with Emedastine Difumarate Sustained-release Capsules, 1 grains/time, twice daily. Patients in the treatment group were po administered with Compound Muni Ziqi Granules on the basis of the control group, 6 g/time, three times daily. Patients in two groups were treated for 15 d. After treatment, the clinical evaluations were evaluated, the symptom relief time, the scores of UAS and GU-Q2oL, the levels of serum IL-33, SAA, D-D and INF-γ in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 95.94%, which was significantly higher than that of the control group (86.49%, P < 0.05). After treatment, the time of symptom relief in the treatment group was significantly earlier than that in the control group (P< 0.05). After treatment, the scores of UAS and GU-Q2oL in two groups were significantly lower (P< 0.05), and the scores in the treatment group were lower than those in the control group (P < 0.05). After treatment, the levels of serum IL-33, SAA and D-D in two groups were significantly decreased, while the level of INF-γ was significantly increased (P < 0.05), and which in the treatment group was significantly better than that in the control group (P< 0.05). Conclusion Compound Muni Ziqi Granules combined with emedastine in treatment of chronic urticaria can effectively improve the clinical symptoms, significantly improve the ability and quality of life of urticaria, and weaken the inflammatory reaction.

R986

河北省醫(yī)學(xué)科學(xué)研究重點(diǎn)課題計(jì)劃項(xiàng)目（20211809）